A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Published:2018-12 Issue:1 Volume:11 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Zhao Wan-Hong,Liu Jie,Wang Bai-Yan,Chen Yin-Xia,Cao Xing-Mei,Yang Yun,Zhang Yi-Lin,Wang Fang-Xia,Zhang Peng-Yu,Lei Bo,Gu Liu-Fang,Wang Jian-Li,Yang Nan,Zhang Ru,Zhang Hui,Shen Ying,Bai Ju,Xu Yan,Wang Xu-Geng,Zhang Rui-Li,Wei Li-Li,Li Zong-Fang,Li Zhen-Zhen,Geng Yan,He Qian,Zhuang Qiu-Chuan,Fan Xiao-Hu,He Ai-Li,Zhang Wang-Gang

Funder

Nanjing Legend Biotech

Grant Major Research Projects Funding Schemes of The Second Affiliated Hospital Of Xi'an Jiaotong University

Key Research and Development Plan of Shaanxi Province, Major Project

Key Research and Development Plan of Shaanxi Province, General Project

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-018-0681-6.pdf

Reference31 articles.

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.

2. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621–9.

3. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–57.

4. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–19.

5. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.

Cited by 406 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

2. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma;Frontiers in Oncology;2024-08-08

3. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study;Pharmaceuticals;2024-08-05

4. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee;The Lancet Oncology;2024-08

5. Finding Your CAR;The American Journal of Pathology;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3